Keros Therapeutics (KROS) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Lyell Immunopharma (LYEL) over the past year, losing 27.1% versus a loss of 51.9%. Over five years, KROS leads with a -70.1% price change compared with -96.7% for LYEL. Keros Therapeutics is the larger company by market cap ($230.8 million vs $215.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | LYEL |
|---|---|---|
| Share price | $11.64 | $8.79 |
| Market cap | $230.79M | $215.40M |
| 1-day change | +3.84% | +2.69% |
| YTD return | -42.83% | -71.44% |
| 1-year return | -27.07% | -51.86% |
| 5-year return | -70.15% | -96.69% |
| EPS (TTM) | $-3.22 | $-13.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $45.00 |
| 52-week low | $9.69 | $8.21 |
| Distance from 52-week high | -48.38% | -80.47% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +70.36% | +330.94% |
| Average volume | 196.01K | 145.70K |
| Shares outstanding | 19.83M | 24.51M |
| Employees | 92 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KROS has outperformed LYEL by 24.8 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
KROS vs LYEL FAQ
Which is bigger, Keros Therapeutics or Lyell Immunopharma?
Keros Therapeutics (KROS) is larger, with a market capitalization of $230.79M compared with $215.40M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, KROS or LYEL?
KROS returned -27.07% over the past 12 months, compared with -51.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.